Cystinuria News

Challenges in diagnosis and treatment of cystinuria patients with Urolithiasis: multicenter patient centered study. Original Story Cystinuria represents a rare cause of urolithiasis, accounting for 1% of all cases. However, it poses [...]

Cystinuria drugs in development, 2024 Original Story The Cystinuria drugs in development market research report provides comprehensive information on the therapeutics under development for Cystinuria, complete with analysis by stage of development, [...]

Cable jointers ascend Snowdon to raise £2K for children’s hospital London News Online Original Story  Cable jointers ascend Snowdon to raise £2K for children’s hospital 31 July 2024Claudia Lee Nine cable jointers [...]

HÜDA PAR submits parliamentary question on cystinuria medication supply HÜDA PAR Batman MP Serkan Ramanlı has submitted a parliamentary question to the Grand National Assembly of Turkey, addressing the difficulties cystinuria patients [...]

Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC® MALVERN, Pa. , July 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of tiopronin delayed-release tablets, a generic [...]

The antioxidant l-Ergothioneine prevents cystine lithiasis in the Slc7a9−/− mouse model of cystinuria Abstract The high recurrence rate of cystine lithiasis observed in cystinuria patients highlights the need for new therapeutic options to address [...]

New tiopronin delayed-release tablets launch with patient support for the treatment of cystinuria in the US Read Full Story BOSTON, May 13, 2024--(BUSINESS WIRE)--Cycle Pharmaceuticals Limited (Cycle) is pleased to announce the [...]

Kids and their battles with kidney stones Ivanhoe Newswire - Apr 28, 2024 - SEE ORIGINAL STORY When you think of kidney stones, you may think of middle-aged men. But that's changed [...]

FDA grants orphan drug designation to ADV7103 for cystinuria Read Original Story Here The FDA has granted an orphan drug designation (ODD) to ADV7103 for the treatment of patients with cystinuria, [...]

Aeglea Cuts Majority of Staff Following Mixed Trial Results Published: Apr 12, 2023 - Original Story Wednesday, Aeglea Biotherapeutics announced it was reducing its headcount as part of a sweeping reorganization following mixed interim data [...]

50 drugs at Mark Cuban's pharmacy with biggest cost reductions Original Story Here In 2023, Mark Cuban Cost Plus Drug Co. began selling two generic medications cheaper than their branded versions [...]

New funding will advance research into the treatment of rare kidney stone disease Dr Malcolm Starkey has received two grants to aid his group’s research on cystinuria, a rare kidney stone [...]